ArriVent BioPharma (AVBP) Q3 2025 earnings summary

Executive summary

• Focused on developing firmonertinib for EGFR-mutant NSCLC, with multiple ongoing clinical trials and recent positive data readouts for uncommon mutations, including PACC and exon 20 insertions; final Phase 1b results showed clinically meaningful progression-free survival and CNS complete responses, supporting advancement to pivotal Phase 3 trials.

• Expanded pipeline with new ADC collaborations (Alphamab, Aarvik, Lepu), including FDA IND clearance for ARR-217, a CDH17-targeted ADC, and ongoing Phase 1 study in China and U.S. IND clearance.

• Appointment of Brent S. Rice as Chief Commercial Officer, bringing over 25 years of global commercial experience.

• No product revenue to date; operations funded by equity offerings and collaborations.

• Cash and investments of $305.4 million as of September 30, 2025, expected to fund operations into mid-2027.

Financial highlights

• Net loss of $34.98 million for Q3 2025, up from $20.56 million in Q3 2024; net loss of $130.8 million for the nine months ended September 30, 2025, compared to $59.9 million for the same period in 2024.

• Research and development expenses rose to $32.17 million in Q3 2025 (from $20.09 million) and $121.2 million for the nine months (from $58.84 million), including a $40 million one-time upfront payment for ARR-217 in-licensing.

• General and administrative expenses increased to $6.15 million in Q3 2025 and $17.54 million for the nine months, reflecting higher personnel and professional costs.

• Cash, cash equivalents, and marketable securities totaled $305.4 million as of September 30, 2025.

• Net cash used in operations was $129.9 million for the nine months ended September 30, 2025, up from $54.1 million in the prior year period.

Outlook and guidance

• Cash runway expected to fund operations for at least 12 months from the reporting date and projected into mid-2027.

• Enrollment of the first patient in the pivotal ALPACCA Phase 3 study for firmonertinib in EGFR PACC mutant NSCLC expected in Q4 2025.

• Top-line pivotal data from the FURVENT Phase 3 trial in EGFR exon 20 insertion mutant NSCLC projected for early 2026.

• Anticipates continued increases in R&D and G&A expenses as pipeline advances and headcount grows.

• Additional ADC programs expected to progress toward the clinic, expanding the pipeline.